Lymphangioleiomyomatosis (LAM) is a proliferation of perivascular epithelioid cells typically affecting the lung as a low-grade, destructive and progressive disease but may also be found in lymph nodes and other organs. LAM is sometimes seen as an incidental finding in lymph node dissections performed for staging of gynecologic tumors. To our knowledge, no study has investigated the clinical significance of incidental nodal LAM in relation to subsequent development of pulmonary LAM. We identified 19 patients from our institution with LAM in lymph nodes. Follow-up was available for 100% of patients and ranged from 3 to 123 months (mean 33.8 mo). All were women, ranging in age from 35 to 71 years (mean 56.3 y). None had a history of tuberous sclerosis, renal angiomyolipoma, or pulmonary LAM. LAM involvement spanned 1 to 6 nodes (mean 2), ranging from 1% to 100% of the total excised lymph nodes. The single largest focus of nodal LAM ranged from 1 to 9 mm (mean 4.3 mm) in 18 patients without evidence of persistent or recurrent nodal LAM. In the 1 patient with persistent local nodal LAM, the greatest diameter was 25 mm. Affected lymph node sites were regional pelvic and retroperitoneal chains routinely sampled in staging operations. An immunohistochemical panel of HMB45, A103, and b-catenin was evaluated in 18 cases. HMB45 showed strong but usually focal staining in every case compared with A103, which was very focally expressed (39%) or negative. bcatenin showed strong, diffuse cytoplasmic and membranous (non-nuclear) reactivity in 100% of cases. At the last clinic visit, all 19 patients had no manifestations of pulmonary LAM. In an absence of signs of symptoms of extranodal LAM, patients with incidentally discovered nodal LAM smaller than 10 mm are not at risk of developing pulmonary LAM.
L ymphangioleiomyomatosis (LAM) is a constituent of the PEComa family of tumors, a family defined by a neoplastic proliferation of perivascular epithelioid cells (PECs) (also called LAM cells in the thoracic literature). 1 Other members in the PEComa family include angiomyolipoma (AML), conventional PEComa (which includes "sugar tumors" and "clear cell myomelanocytic tumors"), and TFE3 translocation-associated PEComa. LAM, like AML, occurs in specific anatomic sites, whereas conventional PEComa and TFE3 translocationassociated PEComa may arise in a variety of organ systems. [2] [3] [4] [5] [6] [7] [8] LAM is most commonly diagnosed in the lung where it behaves as a low-grade, destructive and progressive lung disease. 9 LAM is also found in lymphatics and lymph nodes of the thorax, pelvis, and retroperitoneum, sometimes with equally low-grade and destructive behavior. 10, 11 Patients with pulmonary LAM are typically young women of reproductive age, but rare cases of pulmonary LAM have been described in men. 12 Like other members of the PEComa family, there is an association with tuberous sclerosis (TS), and pulmonary LAM is estimated to develop in 4% to 5% of women with TS. 13, 14 However, the vast majority of patients with pulmonary LAM do not have TS or do not have clinically overt signs of TS despite frequent concurrence of AML of the kidney in 16% to 60% of cases. 11, 15 In patients entirely without signs or symptoms of pulmonary LAM, some investigators have proposed that the presence of nodal LAM may be a high-risk indicator for the development of pulmonary LAM. A study of 22 patients with nodal LAM, 15 the largest to date, found that a diagnosis of nodal LAM preceded development of pulmonary LAM by 1 to 2 years in 11 patients who were otherwise asymptomatic and in another 9 patients who had signs or symptoms related solely to abdominopelvic nodal LAM. The size of nodal LAM in that study tended to be large, ranging from 10 to 200 mm (mean 53 mm), and the total quantity of LAM lesions numbered 1 to 5.
Another cohort of 35 patients with pulmonary LAM found coinciding retroperitoneal lymphadenopathy in 77% and pelvic lymphadenopathy in 11% by CT and/or ultrasound, but lymph node size ranges were not stated. 11 Although there is evidence to link large, bulky nodal LAM as either a harbinger or simultaneously occurring lesion of pulmonary LAM, no study has specifically examined the prognostic significance of small, incidental LAM occasionally identified in lymph nodes resected for unrelated purposes. To better understand the clinical behavior of incidental nodal LAM, we studied a large group of patients, each with follow-up and most of duration exceeding the 1-to 2-year range quoted for expected development of pulmonary LAM. 15 We also evaluated the utility of HMB45, A103, and b-catenin immunohistochemical (IHC) stains in nodal LAM. Diagnosis of LAM in the lung or lymph node may be facilitated by demonstrating expression of melanocytic markers HMB45 or A103, but these stains may sometimes be focal or even negative. 16 Recently, 28 cases of pulmonary LAM were shown to consistently express b-catenin in a strong and diffuse membranous and cytoplasmic pattern. 17 The authors proposed that b-catenin may be a superior marker to traditional IHC in the diagnosis of pulmonary LAM. We evaluated the application of this finding to nodal LAM.
MATERIALS AND METHODS
Cases of LAM involving lymph nodes were retrieved from Memorial Sloan Kettering Cancer Center's (MSK) Department of Pathology. The terms "lymphangioleiomyomatosis" and "lymph node" were used for a search of cases spanning 2004 to 2014. Nineteen cases were identified. Eighteen (cases 1 to 17 and 19) of these were patients whose clinical workup, operative treatment, pathologic evaluation, and postoperative management were performed at MSK. One patient (case 18) had her staging surgery performed at another institution, but all slides processed from this procedure were reexamined at MSK before her receiving postoperative therapy. All hematoxylin and eosin slides were rereviewed to confirm the patients' diagnoses. Clinicopathologic and follow-up data were obtained from the MSK computerized medical record system.
Each case was reexamined to confirm LAM involvement of lymph nodes and any other clinically relevant lesions. These other lesions were the primary purpose of surgery in 18 patients. Nineteen patients had varying degrees of lymph node involvement. The site(s) and total of all surgically sampled lymph nodes, site(s) and total of affected lymph nodes, the largest single focus of LAM as measured by its greatest linear microscopic diameter (done by physically measuring the focus on the glass slide), and the mean of the greatest linear microscopic diameter of all LAMs in lymph nodes if >1 focus was found (foci in close proximity to one another were considered physically distinct if they were 1 mm or more apart) were recorded.
IHC was performed using a panel of 3 antibodies: HMB45 (clone HMB45, no dilution; Ventana Medical Systems, Tucson, AZ), A103 (clone A103, no dilution; Ventana Medical Systems), and b-catenin (clone 14, no dilution; Ventana). The Optiview detection system (Ventana) was utilized with positive and negative controls as necessary.
Immunoreactivity for each stain was graded as either strong (S), weak (W), or absent (0) and then focal/ patchy or diffuse.
RESULTS
Clinical and follow-up data are summarized in Table 1 . The 19 patients with nodal LAM were women No Nodal LAM AWD, 21 mo Treated with AI; node size decreased 2 mo after, but then increased 4 mo later aged 35 to 71 years (mean 56.3 y). None had a history of TS, renal AML, or pulmonary LAM. Eighteen patients had undergone surgery for tumors involving the reproductive tract organs; 16 of these tumors were various forms of Mu¨llerian carcinoma, 1 was an adult granulosa cell tumor, and the other was leiomyomata (this latter patient, case 7, had a history of sarcoidosis and leukemia, which was the clinical basis for lymph node sampling). The remaining patient (case 19) had a laparoscopic resection of a lymph node that was clinically suspected to be lymphoma; she had no history of gynecologic neoplasia.
Follow-up information was available for 100% of patients and ranged from 3 to 123 months (mean 33.8 mo). At last clinic visit, 17 patients were alive with no evidence of pulmonary or nodal LAM, 1 patient had died of serous carcinoma at 23 months after operation but had no evidence of pulmonary or nodal LAM before her death, and the last patient (case 19) showed regional persistence of nodal LAM with no evidence of pulmonary LAM. Case 19 was treated with an aromatase inhibitor and initially showed a radiologic decrease in node size at 2 months, but 4 months later had a rebound increase in affected node size.
With the exception of cases 7 and 19, lymph node sampling was performed as part of surgical staging. The pathologic findings are shown in Table 2 . All lymph node dissections were from pelvic and retroperitoneal chains including the external and internal iliac, common iliac, and para-aortic and aortic lymph nodes and are listed how they were labeled by the submitting surgeon. In some cases, only a regional name was supplied such as "pelvic" lymph nodes. Total lymph nodes excised from each patent ranged from 3 to 52 nodes (mean 22.3). LAM involvement comprised 1 to 6 nodes (mean 2) ranging from 1% to 100% of the total excised lymph nodes.
Analyzing the 18 patients without evidence of recurrent or persistent nodal LAM, the single largest focus The histologic findings of nodal LAM were in keeping with PEComa family of tumors. The PEC can be epithelioid (Fig. 1A) or spindled (Fig. 1B) , but the cytoplasm consistently shows a clear to granular and eosinophilic quality that is classically associated with the PEComa family. In nodal LAM, there was often a mixture of both epithelioid and spindled forms (Fig. 1C ), but finding just 1 morphology was also common. In its epithelioid form, LAM tended to have a nested, lobulated and vaguely swirling architecture that was separated by prominent, sharply defined or cleft-like lymphatic spaces. The spindled form took on a more fascicular growth pattern while preserving the nested or somewhat swirling appearance, but the lymphatic vasculature was less prominent. Bands of dense hyaline collagen were sometimes found intermixed. Neither mitotic activity nor necrosis was seen. Distribution of LAM within the lymph node compartments was variable. Some cases were limited to the subcapsular sinus or hilum (Fig. 1D) , whereas others showed node involvement with extranodal extension ( Fig. 1E) or frank effacement or replacement of the lymph node parenchyma ( Fig. 1F) . Aside from the physical extent of PEC proliferation, there were no morphologic differences in case 19 compared with the other 18 cases.
IHC findings are listed in Table 3 . Tissue blocks were available for IHC in 18 cases. HMB45 was positive in every case with a strong but inconsistently either patchy or diffuse pattern ( Fig. 2A ). A103 was expressed in 7 cases (39%) and was always focal, sometimes labeling no more than 3 or 4 lesional cells. b-catenin was positive in all cases and showed a consistently extensive, strong and diffuse expression in a cytoplasmic and membranous pattern (Fig. 2B) . No nuclear expression was identified.
Other lesions identified in lymph nodes include 1 case with endosalpingiosis and another with endometriosis.
DISCUSSION
Contrasting our findings with observations of prior studies, 10, 11, 15 it is evident that nodal LAM exhibits 2 distinct patterns of proliferation: 1 that is inert and shows no potential for locally or systemically destructive behavior, and the other that is a harbinger or synchronous lesion of pulmonary LAM. What drives nodal LAM to a more aggressive state is unclear. On the basis of our cohort, other than lesion size, there was no outstanding clinical feature, anatomic distribution, or morphologic finding that could distinguish the 18 patients in whom LAM did not recur to the 1 patient in whom it did or in comparison with all other studies of aggressive nodal LAM. However, the significance of lesion size cannot be underappreciated, as an expansile, occlusive and destructive growth of PECs is the very cause of complications in both the lung and lymph node. 9 Investigators have speculated a role for sex hormones owing to the routinely strong IHC expression of estrogen and progesterone receptor in LAM as well as the finding of increased severity of symptoms and disease in pregnant patients with LAM. 18 Further, Yu et al 19 cultured cells from a renal AML in a patient with pulmonary LAM and found that both ERa and ERb receptors are present and that these cells show proliferation when exposed to hormonal stimulation. This same group also noted that tamoxifen, a selective estrogen receptor modulator, was as effective as estrogen in stimulating growth in the same PEC culture. Tamoxifen's capacity to act as both estrogen agonist and antagonist in various human tissues 1 highlights the importance of hormonal stimulation in the release of potent growth factors such as ERK and c-myc.
Other studies have focused on lymphangiogenesis and its role in the progression of LAM. Using antibodies for 2 vascular endothelial growth factors Flt-4 (a marker specific to lymphatic endothelial cells) and VEGF-C, Kumasaka et al 20 assessed patterns of lymphatic production in cases of pulmonary LAM and nodal LAM. They demonstrated an abundance of lymphatic vessels in LAM, both encircling and enmeshed with the lesional cells. This was in comparison with CD31 expression, which was far lower. This same group followed this study with another examining the role these vessels may play in possible dissemination or metastasis of LAM such as from the lung to a lymph node or vice versa. 21 They targeted the lymphatic abnormalities associated with pulmonary and nodal LAM such as chylous effusions, chylous ascites, and chylous cyst formation. Clusters of LAM, enveloped by lymphatic endothelial cells, were found in all chylous specimens. These cell clusters were specifically seen in intra-LAM lymphatic spaces and were then suggested that through LAM-associated lymphangiogenesis small clumps of lesional cells may enter the lymphatic circulation where they may circulate to other organs.
Other data support a metastatic mechanism for the migration of LAM. Karbowniczek et al 22 utilized microsatellite markers and TSC2 gene mutations to analyze a patient with recurrent LAM after single-lung transplantation. They discovered a matching microsatellite signature and an identical somatic 1 base pair deletion in exon 18 of TSC2 in pulmonary and nodal LAM cells in the patient's primary and recurrent LAM. The authors concluded that despite the histologically benign appearance of LAM, it is capable of metastasizing in a subset of patients.
Our data add that it is not the quantity or distribution of nodal lesions that is clinically prognostic, but the largest size of an individual lesion. All 18 patients without recurrent or persistent LAM were under 10 mm in greatest dimension with an average greatest diameter size of 4.3 mm. The finding of 10 mm is relevant when reviewing other reports of nodal LAM that have shown aggressive behavior. In the study of 22 patients by Matsui et al, 15 all patients who subsequently or simultaneously developed pulmonary LAM had nodal manifestations of at least 10 mm. Further, a literature review 23 found similarly large nodal LAM of at least 10 mm was either the initial presenting sign of pulmonary LAM or coexisted with pulmonary LAM. Patient 19 in our series who had locally aggressive nodal LAM had lesions that measured 25 mm in greatest diameter, with an average largest dimension in all her lymph nodes of 14 mm. Whether the size of the lesion is reflective of its internal capacity to proliferate or is being driven by an external source is unknown. Given the proliferative associations of sex hormones and the prevalence of nodal LAM in gynecologic tumor resections identified in our institution, one may reason that an underlying altered hormonal environment induced by a hormone-producing tumor may be a possible explanation. Some gynecologic tumors in our series are capable of producing hyperestrogenic states such as adult granulosa cell tumor or may be the consequence of a hyperestrogenic environment such as low-grade endometrioid carcinoma. However, such cases were the minority in our cohort and we did not appreciate this trend.
The diagnosis of nodal LAM is usually straightforward. Most cases can be identified by hematoxylin and eosin because of the particular morphology and distribution of PECs in the lymph node, but in some settings IHC can be helpful. Flavin et al 17 examined the role of aberrant b-catenin signaling in TS, 24 specifically examining the diagnostic value of b-catenin IHC in pulmonary LAM, and compared expression of HMB45 with b-catenin in 28 cases. They found that all 28 cases demonstrated intense b-catenin labeling with a high specificity and a superior overall immunoreactivity to HMB45. We undertook a similar IHC comparison in our series of nodal LAM and found that HMB45 and b-catenin were the more consistently positive markers in nodal LAM (100% of cases) than A103 (39%). Between HMB45 and b-catenin, we believe the latter is the better marker from an interpretation standpoint: HMB45, although strong, was often punctate and focal in contrast to the diffuse, strong cytoplasmic, non-nuclear pattern of b-catenin.
Some cases of nodal LAM may cause difficulty in the setting of a premenopausal patient with replacement of lymph node(s) by LAM. In this scenario, a diagnosis of leiomyomatosis peritonealis disseminata could be considered in the limited differential. A patient with leiomyomatosis peritonealis disseminata classically presents with multiple small nodules smaller than 10 mm scattered on the peritoneum and in the omentum. 25 The histologic features are in keeping with leiomyomata: a fascicular arrangement of uniformly bland smooth muscle cells. IHC can be helpful, but it is important to recognize that some smooth muscle tumors may exhibit focal expression of HMB45. 26 Therefore, A103 or b-catenin would be our immunostain of choice. As LAM may often be negative for A103, we believe the diffuse pattern of b-catenin is preferable to confirm a suspected diagnosis of LAM.
In summary, we presented 19 patients with nodal LAM, all with long-term follow-up at a single institution, and found no evidence of aggressive behavior or development of pulmonary LAM in 18 patients whose lesion(s) measured no greater than 10 mm. We also advocate use of b-catenin IHC in diagnostically difficult cases for its ease of interpretation.
